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Microbiology, Hospital Vall D’Hebron, Barcelona, 4) Department of
Microbiology, Hospital Clinico de Zaragoza, Zaragoza, 5) Department of
Genetics and Microbiology, UAB, Bellaterra and 6) GEIM (Mycobacterial
Infections Study Group), SpainAbstractTo investigate the potential implications (especially the implications
in clinical signiﬁcance and antimicrobial susceptibility) of
polyclonality among rapidly growing mycobacteria, we performed
random ampliﬁed polymorphic DNA analysis in 64 clinical
isolates of which the clinical signiﬁcance was established.
Phenotypic characteristics (antimicrobial susceptibility test, colony
morphology and growth rate) of each clone were studied.
Polyclonality was detected in 13 of the isolates (20.3%). There
was a relationship between monoclonality and clinical signiﬁcance
(p 0.0096). Monoclonal and polyclonal isolates showed different
behaviour in antimicrobial susceptibility. There was a strong
relationship between monoclonality and those species that are
more pathogenic for humans, and also with clinical signiﬁcance of
the isolates.
Clinical Microbiology and Infection © 2014 European Society of
Clinical Microbiology and Infectious Diseases. Published by
Elsevier Ltd. All rights reserved.
Keywords: Genotypic, polyclonality, random ampliﬁed
polymorphic DNA, rapidly growing mycobacteria, susceptibility
Original Submission: 22 August 2014; Revised Submission:
17 November 2014; Accepted: 6 December 2014
Editor: G. Antonelli
Article published online: 11 December 2014Clin Microbiol Infect 2015; 21: 348.e1–348.e4
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious
http://dx.doi.org/10.1016/j.cmi.2014.12.004Corresponding author: J. Esteban, Avda Reyes Católicos, 2, 28040
Madrid, Spain
E-mail: jestebanmoreno@gmail.comNon-pigmented rapidly growing mycobacteria are a ubiquitous
group of environmental organisms that can be opportunistic
pathogens [1–3]. Polyclonality has been deﬁned as the presence
of different genotypes from the same bacterial species in the
same sample [4]. There are some studies suggesting that the
selection of several clones can occur under stressful conditions
[5], and a hypothesis explaining that different genotypes of
mycobacteria could correspond with their pathogenic role [6],
so the presence of polyclonality is a risk factor that needs to be
researched [7].
Sixty-four clinical isolates (one isolate/patient) from six
Spanish hospitals were studied. All hospitals processed the
samples for mycobacterial culture using internationally stan-
dardized protocols [8]. Identiﬁcation of the isolates was per-
formed by using a PCR-hybridization method (GenoType
Mycobacterium CM/AS System, Hain Lifescience, Nehren,
Germany) or 16S rDNA sequencing. Up to 20 individual col-
onies were randomly picked from the original positive cultures
and re-isolated onto Middlebrook 7H10 agar. Clinical signiﬁ-
cance of the isolates was established following international
guidelines [9]. Random ampliﬁed polymorphic DNA analysis was
performed by using the protocol described by Zhang et al. [10],
using three of the described primers (INS-2, IS986-FP and OPA-
2). PuRe Taq Ready-to-go PCR beads (Amersham Biosciences,
Chalfont St Giles, UK) were used. The ampliﬁcation was con-
ducted in a PTC-100 Peltier Thermal Cycler (MJ Research, St
Bruno, QC, Canada) as follows: 40 cycles at 94°C for 1 min, 36°
C for 1 min and at 72°C for 2 min. To avoid reproducibility
problems, all colonies from the same isolate were analysed
together. We compared patterns using BIOPROFIL BIOGENE
Software (Vilber-Lourmat, Marne la Vallée, France). Difference
among clones was established when two or more high-density
bands were different in at least one of the three primers used.
Phenotypic studies were then performed with one strain from
each clone. Minimum inhibitory concentration was studied for
amikacin, cefoxitin, ciproﬂoxacin, clarithromycin, doxycycline
and linezolid following the standardized broth microdilution test
[11]. A difference between strains was considered if MIC was
different in two or more dilutions. Ten microlitres of a 0.5
McFarland dilution were streaked on Middlebrook 7H10 plates
and incubated at 30°C in normal atmosphere to deﬁne growthDiseases. Published by Elsevier Ltd. All rights reserved
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and colony morphology (smooth or rough).
The main characteristics of the studied strains appear in
Table 1. We detected 13 isolates from a respiratory source
(20.3%) where more than one clone (a picked colony with a
difference in two or more strong bands with at least one
primer set) could be detected. The mean number of clones
was 4.9 clones/isolate (range 2–11). We detected polyclonalityTABLE 1. Description of clinical samples studied
Sample Species of Mycobacterium Polyclonality Num
FJD-1 M. abscessus No 1
FJD-2 M. abscessus No 1
FJD-3 M. abscessus No 1
FJD-4 M. abscessus No 1
FJD-5 M. abscessus No 1
FJD-6 M. abscessus No 1
FJD-7 M. abscessus No 1
FJD-8 M. abscessus No 1
HUB-1 M. abscessus No 1
HUB-2 M. abscessus No 1
HUB-3 M. abscessus No 1
HUB-4 M. abscessus No 1
HUB-5 M. abscessus No 1
HUB-6 M. abscessus No 1
HULP-1 M. abscessus No 1
FJD-9 M. abscessus No 1
HVH-1 M. abscessus No 1
HVH-2 M. abscessus No 1
HVH-3 M. abscessus No 1
HVH-4 M. abscessus No 1
HVH-5 M. abscessus No 1
HVH-6 M. abscessus No 1
HVH-7 M. abscessus No 1
HVH-8 M. abscessus No 1
HVH-9 M. abscessus Yes 6
FJD-10 M. chelonae No 1
HCZ-1 M. chelonae No 1
HUB-7 M. chelonae No 1
HUB-8 M. chelonae No 1
HUB-9 M. chelonae No 1
HUB-10 M. chelonae No 1
HUB-11 M. chelonae No 1
HUB-12 M. chelonae No 1
HUB-13 M. chelonae No 1
HUB-14 M. chelonae Yes 2
FJD-11 M. fortuitum No 1
FJD-12 M. fortuitum No 1
FJD-13 M. fortuitum Yes 3
FJD-14 M. fortuitum Yes 8
FJD-15 M. fortuitum Yes 8
FJD-16 M. fortuitum Yes 8
HCZ-2 M. fortuitum No 1
HCZ-3 M. fortuitum No 1
HCZ-4 M. fortuitum No 1
HCZ-5 M. fortuitum No 1
HCZ-6 M. fortuitum Yes 11
HUB-15 M. fortuitum No 1
HUB-16 M. fortuitum No 1
HUB-17 M. fortuitum No 1
HUB-18 M. fortuitum No 1
HUB-19 M. fortuitum No 1
HUB-20 M. fortuitum No 1
HUB-21 M. fortuitum No 1
HUB-22 M. fortuitum No 1
HUB-23 M. fortuitum No 1
HUB-24 M. fortuitum No 1
HUB-25 M. fortuitum No 1
HUB-26 M. fortuitum Yes 2
HUB-27 M. fortuitum Yes 2
HUB-28 M. fortuitum Yes 3
FJD-17 M. mucogenicum No 1
FJD-18 M. mucogenicum Yes 6
HUB-29 M. mucogenicum Yes 2
HUB-30 M. mucogenicum Yes 2
Abbreviations: FJD, IIS-Fundación Jiménez Díaz; HUB, Hospital Universitari de Bellvitge-IDIB
Hospital Clínico de Zaragoza; R, respiratory; E, extrarespiratory.
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32% Mycobacterium fortuitum and 75% Mycobacterium mucoge-
nicum isolates. Species were grouped in chelonae-abscessus
group (M. abscessus and M. chelonae) and fortuitum group
(M. fortuitum and M. mucogenicum). The chelonae-abscessus
group had 5.7% polyclonal strains, while the fortuitum group
had 37.9% (p 0.00182, Fisher’s exact test). Ninety-six per cent
of clinically signiﬁcant isolates were found to be monoclonalber of clones Sample source Clinical signiﬁcance
R Yes
R Yes
E (node biopsy) No
R Yes
R Yes
R Yes
R Yes
R Yes
R No
R Yes
R Yes
R Yes
R No
R No
R Yes
E (joint ﬂuid) Yes
R Yes
R Yes
R Yes
R Yes
R Yes
R Yes
R Yes
R Yes
R Yes
E(conjunctival abscess) Yes
E (skin biopsy) Yes
R No
R No
R No
E (abscess) No
R No
R No
R No
R No
E (skin exudates) No
R No
R No
R No
R No
R No
R Yes
R Yes
R No
R No
R No
R No
R No
R No
R No
R No
R No
R No
R No
R No
R No
E (skin biopsy) No
R No
R No
R No
R No
R No
R No
R No
ELL; HULP, Hospital Universitario La Princesa; HVH, Hospital Vall D’Hebron; HCZ,
fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 348.e1–348.e4
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isolates (M. abscessus) had clinical relevance.
Antimicrobial susceptibility testing showed the following
percentages of resistance among monoclonal isolates: 8% for
amikacin, 14% for cefoxitin, 40% for ciproﬂoxacin, 12% for
clarithromycin, 84% for doxycycline and no resistances against
linezolid. Antimicrobial susceptibility testing of polyclonal
strains showed differences between clones in seven isolates in
one to three clones. These differences appeared in all of the
antimicrobials except linezolid, and all of the clones susceptible
or intermediately susceptible. There was only one isolate
where all but one of the clones were doxycycline-resistant.
Among polyclonal isolates, resistance was 8% for amikacin,
46% for cefoxitin, 15% for ciproﬂoxacin, 23% for clari-
thromycin, and 92% for doxycycline. Comparing the distribu-
tion of resistances between monoclonal and polyclonal isolates,
the difference for ciproﬂoxacin was statistically signiﬁcant
(p 0.029, Fisher’s exact test).
Rough colonies appeared in 51.6% of the clones (65.6% from
the chelonae-abscessus group). Smooth colonies (48.4% of total)
were mainly from the fortuitum group (53.3%). Two polyclonal
isolates showed mixed morphotypes: M. mucogenicum FJD-17,
which presented 50% of clones for each morphotype, and
M. fortuitum HUB-28, which showed two clones with smooth
colonies and one clone with a rough colony. Growth rate was
different in 8/13 polyclonal samples and varied widely between
3 and 7 days. There was no relationship between species
regarding this property.
These results suggest that there may be a tendency to-
wards monoclonality in those species that are usually more
pathogenic for humans (M. abscessus and M. chelonae), and it
seems to be associated with human diseases. Assuming that
the main source of the mycobacteria would be environmental
[12], and that in nature a mix of different clones from the
same species could be expected; we hypothesize that all of
these clones appear in the ﬁrst stages of colonization. Later, in
some cases, a virulent clone could prevail and ﬁnally infection
develops. On the other hand, with potentially less pathogenic
species, several clones could coexist without infection.
Studies on the possibility of human transmission in cystic
ﬁbrosis patients [13] appear to support our hypothesis,
because long colonization periods can allow pathogenic clone
selection. Ciproﬂoxacin showed a tendency to resistance in
monoclonal samples, but it could be explained because these
isolates were mainly M. chelonae and M. abscessus, which
usually show resistance against quinolones [14]. Because it is
recommended to base treatments on individual susceptibility
testing [14,15], according to our results, several colonies
must be tested to avoid false results that could lead to ther-
apeutic failures.Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectRough colonies have been associated with more severe and
persistent cases of infection [16]. However, we could not afﬁrm
that the presence of rough colonies is related to clinical sig-
niﬁcance [17]. In addition, growth rate does not follow any
pattern that could be related to species or group. This feature
could have an impact on the microbiological analysis, because
clones with a higher growth rate could hinder the detection of
slower growers.
The main limitation of our study is related to the use of
random ampliﬁed polymorphic DNA instead of pulsed ﬁeld gel
electrophoresis or complete chromosome sequencing, but this
technique has been described for rapidly growing mycobacteria
[10] and we have previously used this technique in the same
conditions [18,19]. We think that the strict requisites for iden-
tity of the strains minimize potential failures of the technique.
In conclusion, polyclonality seems to be exceptional in clin-
ically signiﬁcant rapidly growing mycobacteria, but is relatively
common among non-signiﬁcant isolates. Polyclonality has an
inﬂuence in some phenotypic characteristics that could have
therapeutic consequences. Further studies with other meth-
odologies would be needed to completely deﬁne the role of
polyclonality, as well as to evaluate the importance of poly-
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